Hormone Testing Has Limited Clinical Utility for Diagnosing Perimenopause
Diagnose perimenopause based on menstrual history and age, not hormone levels—FSH, LH, and E2 measurements are unreliable for this purpose and should not routinely be ordered. 1
Why Hormone Testing Fails in Perimenopause
The Endocrine Society explicitly states that sex steroids, gonadotropins, inhibin B, or anti-Müllerian hormone measurements do not further inform the diagnosis, do not indicate precisely when the final menstrual period will occur, and will not influence management unless a woman is seeking fertility 1. This is the strongest guideline-level evidence available.
The Problem: Extreme Hormonal Variability
During perimenopause, hormone levels fluctuate wildly both within individual women over time and between different women:
- FSH and E2 show wide ranges even within 3 months of the final menstrual period, with no reliable correlation to age or duration of amenorrhea 2
- Single measurements are meaningless because levels vary cyclically and are not unidirectional in any individual woman 2
- Studies demonstrate that perimenopausal women can have paradoxically elevated E2 levels (79.05 pg/mL) compared to postmenopausal women (25.05 pg/mL), despite also having elevated FSH 3
- FSH can be transiently elevated years before actual menopause, then fluctuate back down 4
When Hormone Testing May Be Considered
The Endocrine Society provides only two narrow exceptions where hormone testing might be useful 1:
- Post-hysterectomy women (without bilateral oophorectomy) where menstrual history is unavailable
- Women with inadequate menstrual history to determine menopausal status
Even in these cases, the guideline recommends:
- Replicate measures (not single tests) of FSH and estradiol
- Making only a presumptive diagnosis when combined with vasomotor symptoms
- Using FSH >40 mIU/mL and E2 <20 pg/mL on multiple occasions as supportive (but not definitive) evidence 1
The Correct Diagnostic Approach
For women with intact uterus: Menopause is diagnosed clinically by cessation of menses for at least 12 months 1. Perimenopause is diagnosed by:
- Irregular menstrual cycles in women typically aged 45-55 years
- Presence of vasomotor symptoms (hot flashes, night sweats)
- No laboratory testing needed
Common Pitfalls to Avoid
- Do not order FSH/E2 to "confirm" perimenopause in women with changing menstrual patterns—this wastes resources and may mislead management
- Do not rely on "normal" FSH or E2 to rule out perimenopause—women can have regular hormone levels despite being perimenopausal 3
- Do not repeat hormone testing to track progression—serial measurements do not predict timing of final menstrual period better than single measures 5
Special Context: Bone Health Monitoring
While FSH/E2 are poor diagnostic tools for perimenopause itself, FSH may have value for predicting bone loss risk in women already known to be in the menopausal transition. Each doubling of FSH associates with 39% greater risk of significant lumbar spine bone loss within one year 5. However, this is a risk stratification tool, not a diagnostic test for perimenopause.
The bottom line: Stop ordering FSH, LH, and E2 to diagnose perimenopause. Use clinical criteria—menstrual pattern changes and age—which are more accurate, less expensive, and actually guide management decisions.